The Royal Marsden NHS Foundation Trust, London and Surrey, UK.
The Royal Marsden NHS Foundation Trust, London and Surrey, UK.
Breast. 2017 Dec;36:54-59. doi: 10.1016/j.breast.2017.07.015. Epub 2017 Sep 29.
Leptomeningeal disease (LMD) is an uncommon complication of advanced breast cancer. The prognosis is poor, and although radiotherapy (RT), systemic and intra-thecal (IT) chemotherapy are accepted treatment modalities, efficacy data are limited. This study was designed to evaluate potential predictors of survival in this patient group.
Breast cancer patients with LMD diagnosed by MRI in a 10-year period (2004-2014) were identified from electronic patient records. PFS and OS estimates were calculated using Kaplan-Meier method, with planned sub-group analysis by treatment modality. Cox regression was employed to identify significant prognostic variables.
We identified 182 eligible patients; all female, median age at LMD diagnosis 52.5 years (range 23-80). Ninety patients (49.5%) were ER positive/HER2 negative; 48 (26.4%) were HER2 positive, and 27 (14.8%) were triple negative. HER2 status was unknown in 17 (9.3%). Initial management of LMD was most commonly whole or partial brain RT in 62 (34.1%), systemic therapy in 45 (24.7%) or supportive care alone in 37 (20.3%). Fourteen patients (7.7%) underwent IT chemotherapy, of whom two also received IT trastuzumab. From diagnosis of LMD, the median PFS was 3.9 months (95%CI 3.2-5.0) and median OS was 5.4 months (95%CI 4.2-6.6). Patients treated with systemic therapy had the longest OS (median 8.8 months, 95%CI 5.5-11.1), compared to RT; 6.1 months (95%CI 4.2-7.9 months), IT therapy; 2.9 months (95%CI 1.2-5.8) and supportive care; 1.7 months (95%CI 0.9-3.0). On multivariable analysis, triple negative histology, concomitant brain metastases, and LMD involving both the brain and spinal cord were associated with poor OS.
Breast cancer patients with triple negative LMD, concomitant brain metastases or LMD affecting both the spine and brain have the poorest prognosis. Clinical trials to identify more effective treatments for these patients are urgently needed.
脑膜疾病(LMD)是晚期乳腺癌的一种罕见并发症。预后较差,尽管放疗(RT)、全身和鞘内(IT)化疗是公认的治疗方法,但疗效数据有限。本研究旨在评估该患者群体生存的潜在预测因素。
从电子病历中确定了 10 年内(2004-2014 年)通过 MRI 诊断为 LMD 的乳腺癌患者。使用 Kaplan-Meier 法计算 PFS 和 OS 估计值,并按治疗方式进行计划的亚组分析。采用 Cox 回归分析识别显著的预后变量。
我们确定了 182 名符合条件的患者;均为女性,LMD 诊断时的中位年龄为 52.5 岁(23-80 岁)。90 名患者(49.5%)为 ER 阳性/HER2 阴性;48 名(26.4%)为 HER2 阳性,27 名(14.8%)为三阴性。17 名(9.3%)患者的 HER2 状态未知。LMD 的初始治疗最常见的是全脑或部分脑 RT,有 62 例(34.1%);全身治疗 45 例(24.7%)或单纯支持治疗 37 例(20.3%)。14 名患者(7.7%)接受了 IT 化疗,其中 2 名患者还接受了 IT 曲妥珠单抗治疗。从 LMD 诊断开始,中位 PFS 为 3.9 个月(95%CI 3.2-5.0),中位 OS 为 5.4 个月(95%CI 4.2-6.6)。接受全身治疗的患者 OS 最长(中位 8.8 个月,95%CI 5.5-11.1),与 RT 相比;6.1 个月(95%CI 4.2-7.9 个月);IT 治疗;2.9 个月(95%CI 1.2-5.8)和支持性护理;1.7 个月(95%CI 0.9-3.0)。多变量分析显示,三阴性组织学、同时性脑转移以及累及脑和脊髓的 LMD 与较差的 OS 相关。
三阴性 LMD、同时性脑转移或影响脑和脊柱的 LMD 的乳腺癌患者预后最差。迫切需要开展临床试验,以确定这些患者更有效的治疗方法。